Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmelo Rizzari

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
Frontiers in Pediatrics|September 22, 2025
Case report: Successful treatment of a patient presenting with a very rare association of acute lymphoblastic leukemia and mucopolysaccharidosis type IVASofia Maria Carlotta Arnaboldi, Martha Caterina Faraguna, Antonella Colombini, et al.
Blood|July 2, 2002
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol IIMaurizio Aricò, Maria Grazia Valsecchi, Valentino Conter, et al.
Pharmaceutical Research|March 28, 2024
Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic LeukemiaLeiah J Brigitha, Veerle Mondelaers, Yiwei Liu, et al.
Haematologica|December 7, 2014
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangementMartina Pigazzi, Elena Manara, Barbara Buldini, et al.
The Lancet Regional Health. Europe|January 8, 2026
Inequalities in availability of clinical trials for pediatric, adolescent, and young adult patients with cancer in Europe: results from the SIOPE OCEAN projectKerstin K Rauwolf, Teresa de Rojas, Miguel Martins, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
Haematologica|March 2, 2016
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivationInge M van der Sluis, Lynda M Vrooman, Rob Pieters, et al.
British Journal of Haematology|May 3, 2019
Acute myeloid leukaemia niche regulates response to L-asparaginaseIlaria M Michelozzi, Valentina Granata, Giada De Ponti, et al.
Blood|February 1, 2007
Ancestry and pharmacogenetics of antileukemic drug toxicityShinji Kishi, Cheng Cheng, Deborah French, et al.
Cancers|January 21, 2022
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) CentersGiuliana Beneduce, Antonia De Matteo, Pio Stellato, et al.
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
Frontiers in Pediatrics|September 22, 2025
Case report: Successful treatment of a patient presenting with a very rare association of acute lymphoblastic leukemia and mucopolysaccharidosis type IVASofia Maria Carlotta Arnaboldi, Martha Caterina Faraguna, Antonella Colombini, et al.
Blood|July 2, 2002
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol IIMaurizio Aricò, Maria Grazia Valsecchi, Valentino Conter, et al.
Pharmaceutical Research|March 28, 2024
Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic LeukemiaLeiah J Brigitha, Veerle Mondelaers, Yiwei Liu, et al.
Haematologica|December 7, 2014
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangementMartina Pigazzi, Elena Manara, Barbara Buldini, et al.
The Lancet Regional Health. Europe|January 8, 2026
Inequalities in availability of clinical trials for pediatric, adolescent, and young adult patients with cancer in Europe: results from the SIOPE OCEAN projectKerstin K Rauwolf, Teresa de Rojas, Miguel Martins, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
Haematologica|March 2, 2016
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivationInge M van der Sluis, Lynda M Vrooman, Rob Pieters, et al.
British Journal of Haematology|May 3, 2019
Acute myeloid leukaemia niche regulates response to L-asparaginaseIlaria M Michelozzi, Valentina Granata, Giada De Ponti, et al.
Blood|February 1, 2007
Ancestry and pharmacogenetics of antileukemic drug toxicityShinji Kishi, Cheng Cheng, Deborah French, et al.
Cancers|January 21, 2022
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) CentersGiuliana Beneduce, Antonia De Matteo, Pio Stellato, et al.
Pageof 15